Bioventus (BVS)
(Delayed Data from NSDQ)
$7.17 USD
+0.10 (1.41%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $7.16 -0.01 (-0.14%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BVS 7.17 +0.10(1.41%)
Will BVS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BVS
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
Encompass Health (EHC) Expands in Louisville With New Rehab Unit
BVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Investors Must Hold on to Centene (CNC) Stock Now
Compelling Reasons to Hold on to Cigna (CI) Stock for Now
Here's Why You Should Consider Buying Bioventus (BVS) Stock
Other News for BVS
Wilsons Reaffirms Their Buy Rating on Bravura Solutions Limited (BVS)
Envoy Medical appoints Michael Crowe to board of directors
Bravura Joins S&P/ASX Tech Index in June Rebalance
3 Stocks Under $10 With Mammoth Growth Prospects
Bioventus management to meet with Craig Hallum